Patents by Inventor Peter Charles ELLIOTT

Peter Charles ELLIOTT has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MULTI-SPECIFIC ANTIBODIES AND ANTIBODY COMBINATIONS
    Publication number: 20240067758
    Abstract: The present invention relates to antibodies binding to IL13 and IL22. The invention provides novel multi-specific antibodies that bind to both IL13 and IL22 and compositions comprising an antibody that binds to IL13 and an antibody that binds to IL22. The invention further relates to therapeutic uses of the combination of anti-IL13 and anti-IL22 antibodies and multi-specific antibodies that bind to both IL13 and IL22.
    Type: Application
    Filed: December 6, 2021
    Publication date: February 29, 2024
    Inventors: Joseph Michael David RASTRICK, John Paul SILVA, Daniel John LIGHTWOOD, Ralph ADAMS, Roger Thomas PALFRAMAN, Kerry Louise TYSON, Peter Charles ELLIOTT, Seema MAYANK, Andrea Julie CROSBY, Emily Mary Cairistine BARRY, Seppe Frans Roman LEYSEN, Zainab AHDASH
  • ANTIBODIES AGAINST INTERLEUKIN-22
    Publication number: 20230416357
    Abstract: The present invention relates to antibodies binding to IL22 and inhibiting its interaction with one or more of its natural ligands Specific examples of such antibodies are provided. The therapeutic uses of the antibodies and methods of generating such C are also provided.
    Type: Application
    Filed: December 6, 2021
    Publication date: December 28, 2023
    Inventors: Joseph Michael David RASTRICK, John Paul SILVA, Kerry Louise TYSON, Peter Charles ELLIOTT, Seppe Frans Roman LEYSEN, Zainab AHDASH
  • ANTIBODIES AGAINST KLK5
    Publication number: 20230075753
    Abstract: The present invention relates to antibodies which bind and inhibit KLK5 and methods of using the same to treat diseases caused by KLK5 imbalance. In particular, the present invention relates to inhibitory antibodies binding KLK5 and their use in the treatment of Netherton disease, atopic dermatitis and cancer.
    Type: Application
    Filed: February 1, 2021
    Publication date: March 9, 2023
    Inventors: Neesha DEDI, Peter Charles ELLIOTT, Seppe Frans Roman LEYSEN, Sean MASON, David James MCMILLAN, Gillian Claire NESS, Niccolo PENGO, Martin Anthony REDHEAD, Alison TURNER, Kerry Louise TYSON
  • ANTIBODIES AGAINST KLK5
    Publication number: 20230070261
    Abstract: The present invention relates to antibodies which bind and inhibit KLK5 and methods of using the same to treat diseases caused by KLK5 imbalance. In particular, the present invention relates to inhibitory anti-KLK5 antibodies and their use in the treatment of Netherton disease, atopic dermatitis and cancer.
    Type: Application
    Filed: February 1, 2021
    Publication date: March 9, 2023
    Inventors: Neesha DEDI, Peter Charles ELLIOTT, Seppe Frans Roman LEYSEN, Sean MASON, David James MCMILLAN, Gillian Claire NESS, Niccolo PENGO, Martin Anthony REDHEAD, Alison TURNER, Kerry Louise TYSON
  • Anti-alpha synuclein antibodies
    Patent number: 11292831
    Abstract: The present invention relates to alpha synuclein binding antibodies and fragments thereof capable of binding alpha synuclein as a monomer and in fibrils and preventing alpha synuclein aggregation induced by alpha synuclein fibrils. The antibodies of the present invention are for use in the treatment of alpha synucleinopathies, including Parkinson's disease.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: April 5, 2022
    Assignee: UCB BIOPHARMA SRL
    Inventors: Patrick Downey, Kerry Louise Tyson, Marco Kriek, Lorenzo De Lichtervelde, Daniel John Lightwood, David James McMillan, Peter Charles Elliott, Terence Seward Baker
  • ANTI-ALPHA SYNUCLEIN ANTIBODIES
    Publication number: 20210101964
    Abstract: The present invention relates to alpha synuclein binding antibodies and fragments thereof capable of binding alpha synuclein as a monomer and in fibrils and preventing alpha synuclein aggregation induced by alpha synuclein fibrils. The antibodies of the present invention are for use in the treatment of alpha synucleinopathies, including Parkinson's disease.
    Type: Application
    Filed: December 13, 2018
    Publication date: April 8, 2021
    Inventors: Patrick DOWNEY, Kerry Louise TYSON, Marco KRIEK, Lorenzo DE LICHTERVELDE, Daniel John LIGHTWOOD, David James MCMILLAN, Peter Charles ELLIOTT, Terence Seward BAKER